{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:27Z","timestamp":1792714287326,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-030570"],"award-info":[{"award-number":["INV-030570"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.isci.2025.113084","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:57:05Z","timestamp":1752616625000},"page":"113084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SARS-CoV-2 vaccines elicit differential Fc effector functions"],"prefix":"10.1016","volume":"28","author":[{"given":"Nelia P.","family":"Manamela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boitumelo M.","family":"Motsoeneng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tandile","family":"Hermanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonkululeko","family":"Mzindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Ayres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanele","family":"Makhado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph","family":"Serage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda G.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-2609","authenticated-orcid":false,"given":"Simone I.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.113084_bib1","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMc2104192","article-title":"Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)","volume":"384","author":"Moyo-Gwete","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.113084_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","article-title":"Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"22","author":"Arora","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.isci.2025.113084_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMc2212117","article-title":"Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6","volume":"387","author":"Hachmann","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.113084_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.113084_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2025.113084_bib10","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2025.113084_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114922","article-title":"Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination","volume":"43","author":"Clark","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.113084_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib13","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMc2202061","article-title":"Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa","volume":"386","author":"Gray","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","article-title":"Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study","volume":"399","author":"Bekker","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.113084_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.113084_bib16","article-title":"Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study","volume":"30","author":"Vikstr\u00f6m","year":"2023","journal-title":"Lancet Reg. Health"},{"key":"10.1016\/j.isci.2025.113084_bib17","article-title":"SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity","volume":"3","author":"Richardson","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.immuni.2022.01.001","article-title":"mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern","volume":"55","author":"Kaplonek","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2025.113084_bib19","doi-asserted-by":"crossref","first-page":"eabn9243","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"Bartsch","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.113084_bib20","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"Anand","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib21","article-title":"Decay of Fc-dependent antibody functions after mild to moderate COVID-19","volume":"2","author":"Lee","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41577-020-0359-5","article-title":"Dissecting antibody-mediated protection against SARS-CoV-2","volume":"20","author":"Zohar","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.113084_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14728222.2021.1907343","article-title":"Targeting Fc effector function in vaccine design","volume":"25","author":"Richardson","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.isci.2025.113084_bib24","article-title":"Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions","volume":"2","author":"Shiakolas","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.113084_bib26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2025.113084_bib27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.113084_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176359","article-title":"Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity","volume":"9","author":"Zimmerman","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2025.113084_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.113084_bib31","article-title":"Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","volume":"2","author":"Gorman","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001609","article-title":"Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26. CoV2. S vaccine study in nonhuman primates","volume":"20","author":"Zhu","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.isci.2025.113084_bib34","article-title":"Fc-gamma receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2","author":"Mackin","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-\u03b3R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.isci.2025.113084_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110174","article-title":"Compartment-Specific Antibody Correlates of Protection to SARS-CoV-2 Omicron in Macaques","volume":"27","author":"Tong","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.113084_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib38","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals","volume":"27","author":"Kustin","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.113084_bib39","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib40","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib41","article-title":"Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.isci.2025.113084_bib42","article-title":"The BNT162b2 (BioNTech\/Pfizer) vaccine had 95% efficacy against COVID-19\u2265 7 days after the 2nd dose","volume":"174","author":"Chagla","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2025.113084_bib43","article-title":"The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at\u2265 14 d","volume":"174","author":"Sacks","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2025.113084_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2025.113084_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.113084_bib46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.isci.2025.113084_bib47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","article-title":"Prior infection with SARS-CoV-2 boosts and broadens Ad26. COV2. S immunogenicity in a variant-dependent manner","volume":"29","author":"Keeton","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.isci.2025.113084_bib48","article-title":"A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses","author":"Tauzin","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111544","article-title":"BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age","volume":"41","author":"Bates","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.113084_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113084_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm2311","article-title":"mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions","volume":"14","author":"Kaplonek","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.113084_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29527","article-title":"SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines","volume":"96","author":"Zedan","year":"2024","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.isci.2025.113084_bib54","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.113084_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00504-x","article-title":"Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26. COV2. S","volume":"7","author":"Barbeau","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.isci.2025.113084_bib56","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2021.36.e311","article-title":"Comparison of antibody response elicited by ChAdOx1 and BNT162b2 COVID-19 vaccine","volume":"36","author":"Kang","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.isci.2025.113084_bib57","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiab593","article-title":"Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines","volume":"225","author":"Naranbhai","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.isci.2025.113084_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-022-00279-8","article-title":"Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine","volume":"19","author":"Liwsrisakun","year":"2022","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.isci.2025.113084_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.994160","article-title":"Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines","volume":"9","author":"Hvidt","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2025.113084_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104886","article-title":"Neutralizing immunity against SARS-CoV-2 Omicron BA. 1 by infection and vaccination","volume":"25","author":"Duan","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.113084_bib61","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chom.2022.04.014","article-title":"Neutralization of SARS-CoV-2 Omicron sub-lineages BA. 1, BA. 1.1, and BA. 2","volume":"30","author":"Evans","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.isci.2025.113084_bib62","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib63","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.113084_bib64","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1002\/jmv.26181","article-title":"Dysregulation of the immune response affects the outcome of critical COVID-19 patients","volume":"92","author":"Wei","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.isci.2025.113084_bib65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.virol.2010.12.016","article-title":"Contributions of humoral and cellular immunity to vaccine-induced protection in humans","volume":"411","author":"Amanna","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.isci.2025.113084_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0331-0","article-title":"Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination","volume":"6","author":"Hulett","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.113084_bib67","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/QAD.0000000000002976","article-title":"Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination","volume":"35","author":"Nduati","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.isci.2025.113084_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005315","article-title":"Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control","volume":"12","author":"Ackerman","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2025.113084_bib69","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct Early Serological Signatures Track with SARS-CoV-2 Survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2025.113084_bib70","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1038\/s41467-022-31556-1","article-title":"Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs","volume":"13","author":"Bekliz","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.113084_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib72","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113084_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39189-8","article-title":"Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination","volume":"14","author":"Tong","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.113084_bib74","article-title":"Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines","volume":"4","author":"Kaplonek","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2025.113084_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.isci.2025.113084_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107619","article-title":"Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines","volume":"26","author":"Van Coillie","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.113084_bib78","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate\u2013carbohydrate interactions are required for high affinity binding between Fc\u03b3RIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.113084_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104408","article-title":"The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees","volume":"87","author":"Van Coillie","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.113084_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110114","article-title":"Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern","volume":"37","author":"Farkash","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2025.113084_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8378","article-title":"Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity","volume":"371","author":"Larsen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.113084_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29793","article-title":"Specific long-term changes in anti-SARS-CoV-2 IgG modifications and antibody functions in mRNA, adenovector, and protein subunit vaccines","volume":"96","author":"Reinig","year":"2024","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.isci.2025.113084_bib83","article-title":"Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles","author":"Kaplonek","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1020844","article-title":"mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine","volume":"13","author":"Buhre","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.113084_bib85","article-title":"SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection","author":"Klingler","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib86","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals","volume":"30","author":"Richardson","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.isci.2025.113084_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients","volume":"6","author":"Geers","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.isci.2025.113084_bib88","article-title":"Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant","volume":"4","author":"Richardson","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113084_bib89","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.113084_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron\u2013reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.isci.2025.113084_bib91","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2025.113084_bib92","doi-asserted-by":"crossref","first-page":"890","DOI":"10.4269\/ajtmh.23-0179","article-title":"Performance of SARS COV-2 IgG anti-N as an independent marker of exposure to SARS COV-2 in an unvaccinated west african population","volume":"109","author":"Abdullahi","year":"2023","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.isci.2025.113084_bib93","article-title":"Safety of the single-dose Ad26. CoV2. S vaccine among healthcare workers in the phase 3b Sisonke study in South Africa","author":"Takuva","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib94","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa","author":"Madhi","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.isci.2025.113084_bib95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.isci.2025.113084_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J. Immunol. Methods"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:53:43Z","timestamp":1786222423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225013458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589004225013458"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.113084","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 vaccines elicit differential Fc effector functions","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.113084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113084"}}